gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RPRXHealthcarePharmaceuticals

Royalty Pharma plc Class A Ordinary Shares (RPRX)

$67.56+1.75%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$66.40▲ 78.02% in range
Nov 3, 2025Low $37.30 · High $67.18Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Royalty Pharma plc closed at $67.56 on Nov 4, up 1.75% — matching its 52-week closing high. Volume of 3.8M shares was 1.17× its 20-day average (close to normal).

Split-adjusted performance: +19.7% over one month, +33.2% over six months, +81.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $674.14M, up 16.5% from a year earlier, with a net margin of 2.7%.

Short interest was 12.8M shares at the Oct 15 settlement (2.9% of float, 4.3 days to cover).

Market cap$30.08B445.3M shares
Revenue · quarter$674.1M+16.5% YoY
Diluted EPS$0.04−42.9% YoY
P/E · TTM36.9×P/S 11.9×
Net margin2.7%Gross 100.0%
Dividend yield1.39%$0.235 last paid
52-week range37.30 – 67.560.0% from high
Volume3.8M1.17× 20-day avg
Volatility · 60d24.8%Annualised
Short % of float2.9%4.3 days to cover
Net cash-$8.23BCash $837.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.2%1M +19.7%3M +18.0%6M +33.2%YTD +74.8%1Y +81.1%3Y +153.0%5Y +83.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum88
Revenue growth63
Net margin71
Value (low P/E)31
Size97

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.8M−0.3% vs prior
Days to cover4.3Settled Oct 15
% of float2.9%
Short vol. 10d50.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RPRXRoyalty Pharma$67.56+1.75%+33.2%+16.5%2.7%36.9$30.08B
ROIVRoivant Sciences$38.23+6.08%+32.7%−33.5%−13164.8%—$27.61BCompare
UTHRUnited Therapeutics$608.49+1.19%+2.0%−1.9%42.5%19.9$26.10BCompare
ZTSZOETIS$89.20+7.48%−19.8%−0.2%28.0%14.1$36.86BCompare
INSMInsmed$110.00+5.32%−19.8%+268.4%−19.1%—$24.13BCompare
VTRSViatris$19.22+1.59%+20.5%+4.9%−3.2%—$22.08BCompare
ALNYAlnylam Pharmaceuticals$161.08+0.74%−46.8%+16.7%148.6%7.9$21.57BCompare
TEVATeva Pharmaceutical Industries Limited$41.85−0.14%+15.2%−0.8%−13.9%69.0$48.81BCompare
JAZZJazz Pharmaceuticals$234.66+2.14%+2.7%+10.4%−38.9%74.0$15.23BCompare

News about Royalty Pharma

All news →
Should You Buy Royalty Pharma Stock Before Nov. 4?The Motley Fool · 6d ago▲ PositiveForget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters InsteadThe Motley Fool · Oct 25, 2026▲ PositiveWhy Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates AgainZacks Investment Research · Oct 8, 2026▲ PositiveRoyalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?The Motley Fool · Oct 1, 2026▲ PositiveRoyalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenGlobeNewswire Inc. · Sep 4, 2026Neutral

Quick answers

What does Royalty Pharma plc do?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products.
What is RPRX's market cap?
$30.08B, based on the Nov 4 close of $67.56.
What is RPRX's P/E ratio?
36.9× trailing-twelve-month earnings of $815M.
Does Royalty Pharma plc pay a dividend?
Yes. The latest regular dividend was $0.235 per share (ex-date Aug 14), an annualised yield of 1.39%.
How much of RPRX is sold short?
12.8M shares, 2.9% of float, as of Oct 15, 2026.
What sector is RPRX in?
Healthcare, in the Pharmaceuticals industry.

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

HQ: New York, NY100 employeesListed Jun 16, 2020royaltypharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology